Denosumab, a RANK ligand inhibitor that reduces osteoclast formation and bone resorption, was investigated in a randomized, double blind, placebo-controlled phase 2 study in patients with erosive hand osteoarthritis (EUDRACT CT 2015-003223-53). touchIMMUNOLOGY were delighted to speak with Dr. Ruth Wittoek (Ghent University, Ghent, Oost-Vlaanderen, Belgium) around the rationale for the use of denosumab in this indication and the aims, design and findings from the study.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Effect of Denosumab on Structure Modification in Erosive Hand Osteoarthritis: Results of a 48-Week, Monocentric, Randomized, Placebo-controlled, Double-blind Phase 2 Study and Open Label Extension Phase.‘ (Abstract number: L05) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What are the unmet needs in the treatment of erosive hand osteoarthritis? (0:20)
- What is the rationale for the use of denosumab in this indication? (1:16)
- What were the aims and design of the clinical trial you are presenting? (1:59)
- What were the primary and secondary endpoints, and how well were they achieved? (3:22)
- What questions remain unanswered about the use of denosumab in this indication, and what further studies are planned? (6:18)
Disclosures: Ruth Wittoek discloses receiving grant/ research support from Amgen.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
